Treatment-emergent AEs were defined as one or both of the following:

• Any AEs with an onset date on or after the study drug start date of parent study and no later than 30 days after permanent discontinuation of study drug in this rollover study;
• Any AEs leading to premature discontinuation of study drug.

Safety Analysis Set included all participants who took at least 1 dose of study drug in the study. The data for this study are summarized by integrating the parent (NCT01659255) study data and rollover study data. One participant in 600 mg arm (CLL), received 40 mg dose for a longer period of time in parent study. Hence, this participant was included in 40 mg arm in safety analysis set.

Treatment-emergent marked laboratory abnormalities were defined as values that increase from baseline by at least 3 toxicity grades at any postbaseline time point, up to and including the date of the last dose of study drug plus 30. If the relevant baseline laboratory value is missing, any Grade 3 or 4 values observed within the timeframe specified above will be considered treatment-emergent marked abnormalities. Laboratory assessments included tests for Chemistry, Hematology, Coagulation and Urinalysis.

Participants in the Safety Analysis Set were analyzed. The data for this study are summarized by integrating the parent study (NCT01659255) data and rollover study data. One participant in 600 mg arm (CLL), received 40 mg dose for a longer period of time in parent study. Hence, this participant was included in 40 mg arm in safety analysis set.

ORR was defined per Modified International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria for CLL and Cheson, 2007 criteria for NHL as percentage of participants who achieve partial response (PR) or complete response (CR) in either parent or roll-over study. CLL:CR: lymphocytes (Ly) <4*10^9/L, no lymphadenopathy,normal spleen and liver size,absence of disease, absolute neutrophil count (ANC) >1.5*10^9/L,platelets ≥100*10^9/L, hemoglobin (Hb) >110 g/L,bone marrow at least normocellular for age; PR: ≥2 of these: ≥50% decrease in Ly, lymphadenopathy,size of liver and spleen, bone marrow infiltrates;and ≥1 of these: ANC >1500/μL, platelets ≥100,000/µL, Hb >11g/dL. NHL:CR: complete resolution of all disease-related radiological abnormalities; PR: ≥50% reduction in sum of products (SPD) of the longest diameters (LD) of all index lesions,no new lesions;no increase in size of liver or spleen;persistence of bone marrow involvement in participant who meets other criteria for CR.

Full Analysis Set consisted of all enrolled participants who took at least 1 dose of study drug in the study. The data for this study are summarized by integrating the parent study (NCT01659255) data and rollover study data.

DOR was defined per IWCLL 2008 criteria for CLL and Cheson, 2007 criteria for NHL as the interval from first documentation of CR or PR to the earlier of the first documentation of definitive disease progression as assessed by the investigator, or death from any cause in subjects who achieve a response. CLL:CR: Ly <4*10^9/L, no lymphadenopathy, normal spleen and liver size, absence of disease, ANC >1.5*10^9/L, platelets ≥100*10^9/L, Hb >110 g/L, bone marrow at least normocellular for age; PR: ≥2 of these: ≥50% decrease in Ly, lymphadenopathy, size of liver and spleen, bone marrow infiltrates; and ≥1 of these: ANC >1500/μL, platelets ≥100,000/µL, Hb >11 g/dL. NHL:CR: complete resolution of all disease-related radiological abnormalities; PR: ≥50% reduction in SPD of the LD of all index lesions, no new lesions; no increase in size of liver or spleen; persistence of bone marrow involvement in participant who meets other criteria for CR.

Participants in the Full Analysis Set with available data were analyzed. Participants who achieved a response are included in the analysis. The data for this study are summarized by integrating the parent study (NCT01659255) data and rollover study data.

PFS was defined per IWCLL 2008 criteria for CLL and Cheson 2007 criteria for NHL as the interval from date of the first dose of tirabrutinib on the parent study to the earlier of the first documentation of definitive disease progression as assessed by the investigator, or death from any cause.

Progressive disease (PD) in CLL: Lymphadenopathy, or appearance of any new lesion/organomegaly, > 50% increase in the size of the liver and/or spleen, Decrease in platelet count or hemoglobin attributable to CLL per IWCLL, Transformation to a more aggressive histology (eg, Richter syndrome).

PD in NHL: Cheson, 2007: Appearance of new lesion or increase by >50% of previously involved sites from nadir, Transformation to a more aggressive NHL histology.

Participants in the Full Analysis Set were analyzed. The data for this study are summarized by integrating the parent study (NCT01659255) data and rollover study data.

OS is defined as the interval from date of the first dose of tirabrutinib on the parent study until death from any cause.

Participants in the Full Analysis Set were analyzed. The data for this study are summarized by integrating the parent (NCT01659255) study data and rollover study data.